GH Research (NASDAQ:GHRS) Stock Price Up 0.2% – Here’s What Happened

GH Research PLC (NASDAQ:GHRS) shares were up 0.2% during trading on Thursday . The company traded as high as $9.70 and last traded at $9.26. Approximately 22,329 shares were traded during trading, a decline of 72% from the average daily volume of 78,940 shares. The stock had previously closed at $9.24.

Analyst Upgrades and Downgrades

GHRS has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of GH Research in a report on Thursday, September 5th. JMP Securities reissued a “market outperform” rating and issued a $39.00 target price on shares of GH Research in a research note on Wednesday, September 4th.

GH Research Stock Up 1.3 %

The business’s 50 day simple moving average is $7.76 and its 200 day simple moving average is $10.37. The stock has a market cap of $472.93 million, a price-to-earnings ratio of -11.51 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.03. Equities research analysts forecast that GH Research PLC will post -0.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP increased its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 80.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,310,563 shares of the company’s stock after buying an additional 1,471,946 shares during the period. GH Research comprises approximately 9.1% of Lynx1 Capital Management LP’s portfolio, making the stock its 6th largest position. Lynx1 Capital Management LP owned 6.36% of GH Research worth $35,291,000 at the end of the most recent quarter. 56.90% of the stock is owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).